Answers are grounded in this paper and cite their sources.
In September and October 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the granting of an EU-wide authorisation for 11 new medicines (Table 1) and 4 new biosimilar medicines (Table 2). The CHMP also recommended the authorisation of 3 new generic medicines and new indications for 16 medicines already authorised in the EU.1,2
No takes yet. Share an insight, caveat, or question.
Sepodes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: